WHO medical eligibility criteria update

Gaffield, Mary Lyn; Kiarie, James

doi:10.1016/j.contraception.2016.07.001

Cited by 18 publications

(23 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We limited our search to manuscripts published in or after 1996, to reflect the publication of the World Health Organization's medical eligibility criteria for contraceptive use; these guidelines were intended for policymakers, program managers and the scientific community as a reference in the development of family planning guidance and methods, and served as an important step forward in contraceptive research and ethics…”

Section: Methodsmentioning

confidence: 99%

“…This systematic review, which was conducted in accordance with a modifi ed version of the PRISMA statement, 24 was part of a large-scale review undertaken to evaluate all qualitative research published from January 1996 to November 2017 on self-reported barriers to and facilitators of use of female-controlled contraceptive methods by women who were medically eligible to use contraceptives. 25 We searched PubMed, Global Health and CINAHL for Englishlanguage, peer-reviewed manuscripts published during the aforementioned time frame; there were no restrictions on study location or participant age. Search terms were chosen on the basis of a preliminary review of published data on contraceptive methods and verifi ed MeSH (medical subject heading) terms.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

A Qualitative Systematic Review of Women's Experiences Using Contraceptive Vaginal Rings: Implications for New Technologies

Vargas

Midoun

Guillen

et al. 2019

Perspect Sexual Reproductive

View full text Add to dashboard Cite

CONTEXT Vaginal rings are available for contraception and hormone replacement, and are being developed as HIV/STD or multipurpose prevention technologies. A comprehensive understanding of women's expectations of and experiences with rings is urgently needed to inform product development and to optimize ring use. METHODS Three databases (PubMed, Global Health and CINAHL) were searched for English‐language, peer‐reviewed articles published between January 1996 and November 2017 that reported qualitative data on barriers to and facilitators of use of female‐controlled contraceptive methods. Data on study methods, findings and conclusions pertaining to contraceptive rings were extracted, organized and analyzed. RESULTS Twenty‐six articles, all published since 2008, met the inclusion criteria. Seven studies focused largely or entirely on rings (and involved current, former or potential users), while the others focused on other contraceptive methods but included ring‐specific data. Familiarity with the ring was low, and women commonly had initial concerns about the method—often related to insertion and removal, cleanliness and discomfort with touching their vagina—that were typically overcome over time. Other major themes were issues related to ring use and discontinuation, the importance of ring‐related properties and characteristics, and considerations related to sexual partners and health care providers. CONCLUSIONS Qualitative data have the potential to inform ring design and promotion. Future research should further explore women's expectations and experiences with the ring, the value of involving male partners in ring evaluation, and evaluation of interventions to improve patient–provider communication concerning ring choice and use.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

A Qualitative Systematic Review of Women's Experiences Using Contraceptive Vaginal Rings: Implications for New Technologies

Vargas

Midoun

Guillen

et al. 2019

Perspect Sexual Reproductive

View full text Add to dashboard Cite

show abstract

“…Adolescence is an optimal time to initiate the discussion surrounding contraception, as only onequarter of teens engaging in sexual behavior are reported to utilize any form of protection against sexually transmitted diseases or pregnancy [9]. Without contraception, up to 85% of women will experience an unintended pregnancy within a year [10]. As the sole healthcare provider to many adolescents with heart disease, cardiologists should view each visit as an opportunity to discuss family planning issues.…”

Section: Cardiologists As Women's Reproductive Health Providersmentioning

confidence: 99%

“…Unlike estrogens, progestins have differing first-pass metabolism rates. Progestin-only contraception does not seem to have the same negative effects on the coagulation cascade as estrogen or combined formulations and therefore can be used in women with higher risks for cardiovascular or thrombotic events [10,22]. The first-and second-generation progestins (norethindrone and levonorgestrel) are estrane derivatives of testosterone with a higher rate of androgenic side effects and thus are more likely to cause bloating, fluid retention, lowering of HDL, and acne than the third-and fourth-generation medications [23].…”

Section: Metabolism and Side Effects Of Hormonal Contraceptivesmentioning

confidence: 99%

“…However, up to 20% also experience irregular and/or intermenstrual bleeding, and this should be taken into consideration when deciding between the two forms of contraception [51]. Other non-cardiac contraindications include current or recent history of breast cancer, severe decompensated liver cirrhosis, hepatocellular carcinoma, and unexplained vaginal bleeding prior to investigation [10,22]. There is no permanent effect on bone mineral density, and the risk of venous thromboembolism, myocardial infarction, or stroke is not increased compared to non-users [18,35].…”

Section: Most Effective With Fewest Contraindications: Intrauterine mentioning

confidence: 99%

See 1 more Smart Citation

Contraception for the Cardiac Patient: a Cardiologist’s Primer

Florio

Kao

Johnson

et al. 2020

Curr Treat Options Cardio Med

View full text Add to dashboard Cite

Purpose of review Cardiovascular disease (CVD) is the number one cause of maternal mortality in the USA. There are many cardiac conditions which pose significant risk to maternal health, and these women should be offered options to avoid unwanted pregnancies. Individualized contraceptive counseling focusing on woman’s desire for future pregnancy, comorbid conditions, and desire for hormone or non-hormonal (contraceptive) options is paramount to avoid adverse or unwanted side effects. The purpose of this review is to give general guidance on prescribing both hormonal and non-hormonal contraceptives for providers caring for women with heart disease. Recent findings Specific recommendation for the use of either non-hormonal or hormonal contraception requires knowledge of the types of contraceptive options available, cost, failure rates, and contraindications to use. Newer progestin-only options have become available and should be considered first-line therapy for women with cardiovascular disease. Summary The physiologic burden of pregnancy on the cardiovascular system can cause significant maternal morbidity and mortality for women with underlying CVD. These women should be offered safe and effective options for birth control, and both cardiology and obstetrical providers alike should possess fundamental knowledge of appropriate options.

show abstract